Annotation Detail
Information
- Associated Genes
- HRAS
- Associated Variants
-
HRAS p.Gly13Asp (p.G13D)
(
ENST00000311189.8,
ENST00000397594.7,
ENST00000397596.6,
ENST00000417302.7,
ENST00000451590.5 )
HRAS p.Gly13Asp (p.G13D) ( ENST00000311189.8, ENST00000397594.7, ENST00000397596.6, ENST00000417302.7, ENST00000451590.5 ) - Associated Disease
- skin squamous cell carcinoma
- Source Database
- CIViC Evidence
- Description
- In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy, a patient harboring HRAS G13D co-mutation (n=1) was reported to be resistant to vemurafenib treatment.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/3851
- Gene URL
- https://civic.genome.wustl.edu/links/genes/2747
- Variant URL
- https://civic.genome.wustl.edu/links/variants/274
- Evidence Type
- Predictive
- Disease
- Skin Squamous Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Vemurafenib
- Evidence Level
- C
- Clinical Significance
- Resistance
- Pubmed
- 22256804
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Vemurafenib | Resitance or Non-Reponse | true |